

Sublocade® (buprenorphine extended-release) – Updated indication

- On February 24, 2025, <u>Indivior announced</u> the FDA approval of <u>Sublocade (buprenorphine</u> <u>extended-release)</u>, for the treatment of moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a **single dose of a transmucosal buprenorphine product** or who are already being treated with buprenorphine.
 - Sublocade was previously approved for the treatment of moderate to severe OUD in patients who have initiated treatment with a buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days.
- The updated indication allows for use of Sublocade as a part of a rapid initiation protocol.
- The approval of Sublocade for the updated indication was based on data from a randomized, open-label study in 723 treatment-seeking patients with moderate to severe OUD and high-risk opioid use. Patients were randomized to Sublocade rapid induction or standard induction. The primary endpoint was the participant retention at the second injection.
 - The proportion of participants who received the second injection was 66.4% in the rapid induction arm and 54.5% in the standard induction arm; the estimated retention rate difference in the overall population was 11.8% with a lower bound of multiplicity adjusted two-sided 95% CI greater than the pre-specified non-inferiority margin of -10%.
 This demonstrates the pre-inferiority is demonstrated by a participant.
 - This demonstrated non-inferiority of rapid induction to standard induction.
- Sublocade carries a boxed warning for risk of serious harm or death with intravenous administration
 - Sublocade is only available through a restricted program called the Sublocade REMS program.
- The most common adverse reactions (≥ 5%) with Sublocade use were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain.
- Sublocade is administered subcutaneously and is for healthcare provider preparation and administration only.
 - Sublocade must be injected into the subcutaneous tissue of the abdomen, thigh, buttock, or back of the upper arm.
 - Refer to the Sublocade drug label for complete dosing and administration recommendations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.